Mallinckrodt 2020

Advancing ECP Immunomodulation Investigator Award in Graft versus host disease:
Refining THERAKOS ECP Immunomodulation™

Frequently Asked Questions

Clinicians, physicians, scientists or others who are interested in ECP Immunomodulation based in the EMEA region* are encouraged to apply. We would like to encourage especially young clinicians and scientists to submit their proposals for evaluaton.

One educational grant of €75,000 will be awarded to the institution and is to be used in the specified timeframe of 18 months.

Yes, this award is designed to go to an institution.

The Investigator Award Committee will consist of Medical Scientists employed by Mallinckrodt Pharmaceuticals. The Award Committee will score applications based on the criteria outlined in the submission form – specifically on scientific merit, its novelty and feasibility – to select a winner as well as a runner-up.

Yes, the awardee is required to share the outcomes of the research through a report at the completion of the project, the exact details on reporting and potential publications will be defined in a contract agreement.

If case your project does not fit the above-mentioned criteria or has been rejected you can still apply for an investigator initiated research program following the link at:

*Austria, Belgium, Croatia, Cyprus, Czech Republic, Denmark, Egypt, Finland, France, Germany, Greece, Hungary, Iceland, Ireland, Israel, Italy, Jordan, Netherlands, Norway, Poland, Portugal, Saudi Arabia, Slovenia, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, United Kingdom.

For any question not answered in our FAQs please contact: